Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB19 hours ago · The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies...
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics …
WEB16 hours ago · The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market.
Press Release: Dupixent approved in the US as the first-ever ... - Sanofi
WEBSep 27, 2013 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB19 hours ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up...
INVESTORS & MEDIA - newsroom.regeneron.com
WEB19 hours ago · Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB19 hours ago · Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD. Drug is cleared for 300,000 U.S. patients with a form of the lung disease driven by eosinophils. Wikimedia Commons. By...
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's …
WEB19 hours ago · The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies...
Regeneron and Sanofi Provide Update on Dupixent® …
WEBOct 20, 2023 · Regeneron and Sanofi remain committed to working with the FDA to advance the study of Dupixent for patients living with CSU who are inadequately controlled by antihistamines. The potential use of Dupixent in CSU is currently under clinical development, and the safety and efficacy have not been …
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
WEB1 day ago · Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Sanofi US News
WEBMay 20, 2024 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent and itepekimab.